Transcon® PTH Phase 3 Data Shows Sustained Response in Adults with Hypoparathyroidism
Ascendis Pharma released 3.5-year data from its Phase 3 PaTHway Trial for TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism....
BiomX Initiates Phase 2b Trial of BX004 in Cystic Fibrosis Patients
BiomX Inc. initiated patient dosing in its Phase 2b trial for BX004, a phage therapy targeting antibiotic-resistant •Pseudomonas aeruginosa•...
Summit Max Clinical Trial Shows Real-World Results
Route 92 Medical announced positive real-world results for its HiPoint Reperfusion System, a catheter system used to treat acute...
Ovaprene® Phase 3 Trial Shows Promise as Novel Non-Hormonal Contraceptive
Daré Bioscience announced positive interim safety and efficacy results from its Phase 3 clinical trial of Ovaprene, a hormone-free,...
Evkeeza Approved for HoFH in Infants by Health Canada
Health Canada has expanded the approval of Evkeeza (evinacumab) to include children as young as six months old with...
Brain Fitness Tracker Validated for Aging Independently
A new four-minute online assessment, Freeze Frame, developed by Posit Science, has been validated as a scientific measure of...
Firefly Inks Deal for Precision Neuroscience Research
Firefly Neuroscience is collaborating with Prof. Dr. med. Christian Schaaf of Heidelberg University Hospital on a study investigating the...
Amtagvi® Shows 49% Response Rate in Advanced Melanoma Patients
Iovance Biotherapeutics announced positive real-world data for its commercially available melanoma treatment, Amtagvi (lifileucel). A study of 41 patients...
Bria-IMT™ Shows Survival Advantage in Metastatic Breast Cancer
BriaCell Therapeutics Corp. announced positive Phase 2 survival data for its lead immunotherapy candidate, Bria-IMT, combined with an immune...
Capricor Provides Deramiocel-BLA Update for Duchenne Muscular Dystrophy
Capricor Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for Deramiocel,...